Efficacy of hyoscine butylbromide versus drotaverine hydrochloride on duration of active phase of labour among term parturients at Nauth, Nnewi: double-blind randomised controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202607885056142

Enrollment

210

Registered

2026-07-24

Start date

2026-08-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth

Interventions

Placebo

Hyoscine butylbromide

Drotaverine hydrochloride

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: • Pregnant women at term, defined as gestational age from 37+0 to 41+6 weeks. • Singleton pregnancy. • Fetus in cephalic presentation. • Active phase of labour with cervical dilatation of 4-5 cm at recruitment. • Age 18 years and above. • Willingness to participate and provision of written informed consent.

Exclusion criteria

Exclusion criteria: • Previous cervical surgery or significant cervical trauma. • Contraindication to vaginal delivery. • Multiple pregnancy. • Non-cephalic presentation. • Medical illness that may affect labour or safety, such as severe preeclampsia, cardiac disease. • Known allergy to hyoscine butylbromide or drotaverine hydrochloride.

Design outcomes

Primary

Measure	Time frame
•Mean duration of the active phase of labour.	—

Secondary

Measure	Time frame
• the need for augmentation of labour • the need for neonatal resuscitation	—

Countries

Nigeria

Contacts

Public ContactChiemezie Agbanu

Senior Registrar

agbanufrank@gmail.com+2348138611735

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 10, 2026